|Bid||293.00 x 800|
|Ask||302.00 x 1100|
|Day's range||292.09 - 300.07|
|52-week range||263.30 - 380.76|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||44.35|
|Earnings date||22 Apr 2020 - 26 Apr 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||338.75|
Illumina, Inc. (NASDAQ:ILMN) shares fell 9.2% to US$290 in the week since its latest full-year results. Illumina...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20 years later, Mammoth Biosciences is hoping to do the same thing for gene editing tools. The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more precise editing tools for genetic material.
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Illumina (ILMN) delivered earnings and revenue surprises of 6.92% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - Illumina (NASDAQ:ILMN) reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
(Bloomberg Opinion) -- When the world’s competition police reflect on big tech’s dealmaking over the past 15 years, you could forgive them for wondering what might have been. If Facebook Inc. hadn’t acquired WhatsApp or Instagram, or if Google hadn’t bought YouTube or DoubleClick, would there be stronger competition for the two Silicon Valley firms?It certainly seems that regulators, particularly in the U.K., are eager to avoid repeat scenarios where companies grab outsize control of an emerging market before it’s clear exactly how important or big that market may be. That’s why a 6.1 billion-pound ($8 billion) food delivery takeover may have broader implications for tech giants’ dealmaking-to-come.Britain’s Competition and Markets Authority is reviewing the Dutch firm Takeaway.com NV’s planned acquisition of Just Eat Plc, the U.K.’s online marketplace for restaurant delivery. It’s a remarkable step, given that Takeaway.com no longer has a British business, and so the two firms don’t currently compete, at least not in the U.K. The regulator, the CMA, is instead pondering hypotheticals. It’s deliberating whether, without a deal, Takeaway.com might still otherwise enter the market and add a healthy dose of competition.The move underscores a recent approach that could make it more difficult for tech giants to make acquisitions, even small ones. (Together, they’ve bought more than 250 companies in the last six years.) Companies might not obviously compete with the firm acquiring them, but the U.K. watchdog is increasingly taking into account the possibility they could become a competitor at some later stage. It seems to have listened to the findings of the government-commissioned review into digital competition last year by Jason Furman, previously economic adviser to former U.S. President Barack Obama, which recommended that the CMA should take “more frequent and firmer action to challenge mergers that could be detrimental to consumer welfare through reducing future levels of innovation and competition.”Across the Atlantic, DNA-sequencing firm Illumina Inc.’s scuppered $1.2 billion acquisition of smaller peer Pacific Biosciences of California Inc. also illustrates the challenge. Both firms are active in slightly different parts of the market, so do not directly compete: Illumina currently focuses on so-called short-read sequencing platforms, while PacBio’s expertise is in long-reads. Yet antitrust authorities in both the U.K. and U.S. pushed back against the deal because of concerns that Illumina would decide against developing its own long-read offering further down the line, according to Bloomberg Intelligence analyst Aitor Ortiz. The firms called the deal off earlier this month.It’s healthy that technology deals are likely to attract more scrutiny. Acquisitions sometimes look like a catch-and-kill strategy: buying a startup that could become a rival before it's able to do so without necessarily using it to augment the business directly. For example, back in 2017, Facebook bought the fast-growing teen app tbh, before shutting it down just eight months later, citing low usage.But doing so presents a potential challenge for the CMA: ensuring that the U.K. remains an attractive place to found technology firms. Venture capitalists and big companies themselves often argue that a lot of startups are founded with the intention of ultimately selling themselves to a larger rival. If that exit strategy disappears, runs the argument, then they might decide to set up shop elsewhere.So far, it’s too early to determine whether that argument has any merit. And analysts still expect the Takeaway.com-Just Eat deal to complete, albeit with a slight delay. But because the CMA has the authority to impose remedies without a court case, unlike the U.S.’s Federal Trade Commission, technology firms have good reason to be wary.To contact the author of this story: Alex Webb at firstname.lastname@example.orgTo contact the editor responsible for this story: Melissa Pozsgay at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Alex Webb is a Bloomberg Opinion columnist covering Europe's technology, media and communications industries. He previously covered Apple and other technology companies for Bloomberg News in San Francisco.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome.
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year, non-exclusive collaboration agreement to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. As the understanding of genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.